Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194149 | 0.82 | VCAM1 (0.54) | RECQLALDH1A1VCAM1LMNATSHR | |
| SCHEMBL2062176 | 0.77 | RECQL (0.52) | RECQLALDH1A1VCAM1LMNATDP1 | |
| SCHEMBL29830207 | 0.77 | MEN1 (0.61) | ALDH1A1TSHRGAAKMT2APOLB | |
| SCHEMBL13232257 | 0.77 | MAPT (0.61) | ALDH1A1KAT2BLMNATSHRTDP1 | |
| SCHEMBL362030 | 0.75 | RAB9A (0.46) | RECQLALDH1A1VCAM1LMNATSHR | |
| SCHEMBL8542184 | 0.75 | GLA (0.65) | RECQLALDH1A1LMNATDP1GAA | |
| SCHEMBL8434723 | 0.73 | RECQL (0.70) | RECQLALDH1A1VCAM1LMNATSHR | |
| SCHEMBL8446303 | 0.73 | RECQL (0.67) | RECQLALDH1A1KAT2BVCAM1LMNA | |
| SCHEMBL8440501 | 0.73 | RECQL (0.59) | RECQLALDH1A1VCAM1LMNATDP1 | |
| SCHEMBL9373869 | 0.73 | RECQL (0.66) | RECQLALDH1A1KAT2BVCAM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| CN-101535276-B | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC | 2013-08-28 | — | — | CN | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101535276-A | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | RECQL 2146/4885ALDH1A1 77/4885KAT2B 3854/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | RECQL 2146/4885ALDH1A1 77/4885KAT2B 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.